Staar Surgical (NASDAQ:STAA) Stock

Staar Surgical

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

bz_pharma_briefs

Analyst Color

Earnings

News

Guidance

Downgrades

Health Care

Analyst Ratings

Movers

Trading Ideas

General

STAA

Staar Surgical posted a Q4 2024 revenue decline due to weak China sales. The company plans cost-cutting measures.

Eye Lens Maker Staar Surgical Stock Sinks As Sales Drop To $49 Million, Analyst Downgrades

Analysts expect Ford Motor Co. (NYSE: F) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.

Markets

ACLS

ONON

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Movers_Stocks

Pre-Market Outlook

ALSN

LYFT

SMWB

SPIR

Teradata Posts Weak Revenue, Joins Lyft, Vertiv, Zillow And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Staar Surgical Co

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $28 to $17.

Price Target

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $17

<h3>Gainers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 107.0% to $1.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $62.1 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares rose 76.29% to $0.41. The company's market cap stands at $3.4 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares rose 34.25% to $0.51. The market value of their outstanding shares is at $18.0 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 33.87% to $0.21. The market value of their outstanding shares is at $1.9 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares rose 28.69% to $10.81. The market value of their outstanding shares is at $86.4 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares increased by 24.5% to $1.77. The company's market cap stands at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) shares declined by 33.8% to $14.49 during Wednesday's pre-market session. The market value of their outstanding shares is at $714.0 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) shares fell 21.88% to $8.5. The market value of their outstanding shares is at $51.7 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock declined by 14.51% to $1.65. The company's market cap stands at $3.7 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock declined by 11.48% to $0.27. The company's market cap stands at $19.6 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 11.3% to $0.17. The market value of their outstanding shares is at $1.4 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares declined by 10.01% to $0.18. The company's market cap stands at $6.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

INAB

KALA

KDLY

LIXT

NKGN

OCEA

TIVC

WINT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

In the latest quarter, 4 analysts provided ratings for Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current average is 32.85% lower than the prior average price target of $34.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739390453_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Staar Surgical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Staar Surgical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>A Deep Dive into Staar Surgical's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.31%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Staar Surgical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Staar Surgical's ROE excels beyond industry benchmarks, reaching 2.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Staar Surgical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Staar Surgical's Future

On Tuesday, Staar Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported a fourth-quarter 2024 EPS loss of 69 cents, a turnaround from an income of 16 cents, missing the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus loss of 16 cents</a>.
The contact lens maker reported sales of $48.95 million, compared to $76.3 million in the prior year quarter, missing the consensus of $77.3 million.
The decrease was due to a significant decline in China revenue, driven by worsening trends in overall <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43639788/staar-surgical-reports-fourth-quarter-and-fiscal-year-2024-results" rel="noreferrer noopener">refractive procedure volumes</a>.
Implantable Collamer Lens&nbsp;(ICL) sales were $46.9 million for the fourth quarter of 2024 compared to $74.6 million in the prior year quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Excluding China, ICL sales were $39.5 million, an increase of 17%.
In December 2024, the company shipped $27.5 million of ICLs to China, for which it did not recognize revenue due to extended payment terms with its distributor.
The company determined to keep product in-country before the anticipated demand rebound in the second half of 2025 and mitigate potential impacts from geopolitical and tariff changes.
Based on the extended payment terms, Staar Surgical expects to receive full payment and fully recognize this revenue by the end of the fiscal quarter ending September 26, 2025.
The gross profit margin for the fourth quarter of 2024 was 64.7% compared to 79.6% a year ago.
Guidance: Staar Surgical expects 2025 ICL sales Ex. China of approximately $165 million to $175 million, representing approximately 9% to 15% growth, assuming overall refractive procedure volumes in the Americas will be down 5%-10%; EMEA will be flat; and APAC Ex. China will be flat.
China&#8217;s ICL sales will be less than $5 million for the first half of 2025, as the company works through elevated inventory levels against weak demand for refractive in-market procedures.
The company sees China ICL sales of approximately $75 million-$125 million in the second half of 2025, which is dependent on overall refractive procedure volumes in China, which the company believes could be down 10% at the low end.
The high end of this range contemplates a rebound in overall refractive procedure volumes growing 10%.
In fiscal year 2025, the company says it will manage its working capital and implement appropriate cost-cutting measures in light of the lower revenue forecast.
The company intends to lower production output, decrease capital expenditures, and make targeted reductions to operating expenses, which will impact headcount and discretionary spending.
Based on the company's outlook for fiscal year 2025, Staar Surgical no longer expects to achieve its Vision 2026 Target Sales and Operating Model, initially announced in September 2023.
William Blair downgraded Staar Surgical to <a target="_blank" href="https://www.benzinga.com/quote/STAA/analyst-ratings" rel="noreferrer noopener">a Market Perform rating</a> given the lack of visibility, uncertainty around stimulus to date, and increasing competition in the region amid what appears to be another year of global refractive market contraction in 2025.
Price Action: Staar Surgical stock is down 38.6% at $13.44 during the premarket session on last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43653433/softbank-q3-earnings-revenue-rises-vision-fund-takes-2-33-billion-hit-as-investments-falter" target="_blank" rel="noreferrer noopener">SoftBank Q3 Earnings: Revenue Rises, Vision Fund Takes $2.33 Billion Hit As Investments Falter</a></li>
</ul>

Stifel analyst Thomas Stephan maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Buy and lowers the price target from $38 to $20.

Stifel Maintains Buy on Staar Surgical, Lowers Price Target to $20

Stephens &amp; Co. analyst Mason Carrico reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Equal-Weight and maintains $28 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Staar Surgical, Maintains $28 Price Target

Piper Sandler analyst Matt O'Brien maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Neutral and lowers the price target from $40 to $16.

Piper Sandler Maintains Neutral on Staar Surgical, Lowers Price Target to $16

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Richard Edwards downgraded the rating for On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) from Buy to Neutral and maintained the price target of $57. On Holding shares closed at $53.97 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) from Overweight to Neutral and lowered the price target from $145 to $115. PPG shares closed at $114.91 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Margaret Kaczor downgraded the rating for STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) from Outperform to Market Perform. STAAR Surgical shares closed at $21.88 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Edward White downgraded MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) from Buy to Neutral. Inhibikase Therapeutics shares closed at $10.18 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Jed Dorsheimer downgraded the rating for Axcelis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) from Outperform to Market Perform. Axcelis Technologies shares closed at $59.30 on Tuesday. <a href="https://www.benzinga.com/quote/acls/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PPG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12091644/image-2-33-1024x601.png" alt="" class="wp-image-778809" style="width:531px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12091644/image-2-33-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12091644/image-2-33-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12091644/image-2-33-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12091644/image-2-33.png 1090w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.
Shares of Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) fell sharply in today's pre-market trading after the company missed fourth-quarter revenue estimates and announced its CFO Claire Bramley will <a href="https://www.benzinga.com/quote/TDC">leave effective March 31</a>.
Teradata reported quarterly earnings of 53 cents per share which beat the analyst consensus estimate of 43 cents per share. The company reported quarterly sales of $409.00 million which missed the analyst consensus estimate of $414.94 million.
Teradata shares dipped 13.1% to $26.86 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Spire Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NASDAQ">SPIR</a>) shares fell 49.6% to $10.00 in pre-market trading. In a new filing released after the market close on Tuesday, Spire Global announced that it filed a complaint in the Delaware Court of Chancery alleging Kplerfailed to close on the acquisition of Spire's maritime business.</li>
<li>STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) shares fell 33.7% to $14.50 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Similarweb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) fell 26% to $12.41 in pre-market trading following weak quarterly earnings.</li>
<li>OneStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) fell 16.7% to $25.15 in pre-market trading following quarterly results.</li>
<li>BlackLine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) dipped 14.8% to $53.99 in pre-market trading after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued FY25 guidance below estimates.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) shares dipped 12.3% to $12.60 in pre-market trading following fourth-quarter results.</li>
<li>Allison Transmission Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) declined 7.2% to $106.00 in pre-market trading after the company issued FY25 revenue guidance below estimates.</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) declined 6.7% to $114.99 in pre-market trading following quarterly results.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) fell 5.8% to $78.98 in pre-market trading after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued first-quarter revenue guidance below estimates..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>

Teradata Posts Weak Revenue, Joins Lyft, Vertiv, Zillow And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock moved upwards by 49.4% to $0.24 during Wednesday's pre-market session. The company's market cap stands at $2.1 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares increased by 41.66% to $11.9. The company's market cap stands at $95.2 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) stock increased by 37.37% to $17.0. The company's market cap stands at $517.2 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock increased by 20.99% to $1.72. The company's market cap stands at $10.2 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares rose 12.35% to $6.0. The market value of their outstanding shares is at $315.7 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) shares rose 12.26% to $0.22. The market value of their outstanding shares is at $12.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) shares declined by 36.7% to $13.85 during Wednesday's pre-market session. The market value of their outstanding shares is at $682.4 million. The company's, Q4 earnings came out yesterday. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock declined by 17.1% to $1.6. The market value of their outstanding shares is at $3.5 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock decreased by 16.25% to $0.17. The company's market cap stands at $5.8 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock decreased by 11.45% to $0.27. The company's market cap stands at $19.6 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares declined by 9.24% to $0.18. The market value of their outstanding shares is at $1.5 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock decreased by 8.31% to $2.65. The company's market cap stands at $80.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANAB

OMGA

SKYE

WIIM

Staar Surgical shares are trading lower after the company reported worse-than-expected Q4 financial results. William Blair downgraded the stock from Outperform to Market Perform.

Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) from Hold to Hold.

Needham Reiterates Hold on Staar Surgicalto Hold

William Blair analyst Margaret Kaczor downgrades Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) from Outperform to Market Perform.

William Blair Downgrades Staar Surgical to Market Perform

Shares of Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY25 revenue guidance <a href="https://in.benzinga.com/25/02/43641265/upstart-q4">above estimates</a>.
Upstart reported quarterly earnings of 26 cents per share which beat the analyst consensus estimate of losses of 4 cents. Quarterly revenue clocked in at $218.96 million which beat the analyst consensus estimate of $182.18 million and is an increase over sales of $140.31 million from the same period last year.
Upstart Holdings shares jumped 25.5% to $84.52 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) gained 75% to $0.4630 in pre-market trading after gaining over 3% on Tuesday.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) rose 57.3% to $0.2516 in pre-market trading after adding 13% on Tuesday.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares jumped 42% to $2.03 in pre-market trading after jumping around 13% on Tuesday.</li>
<li>Omega Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) gained 38.5% to $0.2678 in pre-market trading after jumping 79% on Tuesday. Omega Therapeutics recently said that its estructuring committee approved a workforce reduction of up to 17 employees for cost-reduction amid a Chapter 11 case and potential asset sale.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) gained 37.3% to $0.7828. FangDD announced a $5,000,000 senior convertible notes offering.</li>
<li>Haoxi Health Technology Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) shares climbed 25.1% to $2.2900 in pre-market trading. Haoxi Health Technology recently regained Nasdaq compliance.</li>
<li>Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) gained 19.2% to $59.69 in pre-market trading following fourth-quarter results.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) gained 18.4% to $14.65 in pre-market.</li>
<li>Sonic Automotive, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) gained 6.6% to $79.68 in pre-market trading ahead of quarterly earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Spire Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NASDAQ">SPIR</a>) shares fell 49.6% to $10.00 in pre-market trading. In a new filing released after the market close on Tuesday, Spire Global announced that it filed a complaint in the Delaware Court of Chancery alleging Kplerfailed to close on the acquisition of Spire's maritime business.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) dipped 42% to $20.00 in pre-market trading after dipping over 12% on Tuesday.</li>
<li>Atomera Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) fell 37.8% to $5.37 in today's pre-market trading after the company posted fourth-quarter earnings.</li>
<li>STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) shares fell 33.7% to $14.50 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Similarweb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) fell 26% to $12.41 in pre-market trading following weak quarterly earnings.</li>
<li>Society Pass Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) shares tumbled 25.6% to $4.26 in pre-market trading after jumping 120% on Tuesday.</li>
<li>The LGL Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGL#NYSE">LGL</a>) declined 25.4% to $5.01 in pre-market trading.</li>
<li>OneStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) fell 16.7% to $25.15 in pre-market trading following quarterly results.</li>
<li>Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) fell 13.1% to $26.86 in pre-market trading after the company missed fourth-quarter revenue estimates.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) shares dipped 12.3% to $12.60 in pre-market trading following fourth-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>

APGE

ATOM

MYNA

SOPA

UPST

Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Staar Surgical shares are trading lower after the company reported worse-than-expected Q4 financial results.

Staar Surgical Sees FY25 Incluidng Sales Ex. China ~$165M-$175M

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.16) by 331.25 percent. This is a 531.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $48.950 which missed the analyst consensus estimate of $77.285 million by 100.00 percent. This is a 100.00 percent decrease over sales of $76.273 million the same period last year.

Earnings Misses

Staar Surgical Q4 2024 GAAP EPS $(0.69) Misses $(0.16) Estimate, Sales $48.950 Miss $77.285M Estimate

On January 17, BROADWOOD PARTNERS LP, 10% Owner at Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000718937/000091957425000375//Archives/edgar/data/718937/000091957425000375/0000919574-25-000375-index.htm">U.S. Securities and Exchange Commission</a> on Friday, LP increased their investment in Staar Surgical by purchasing 29,376 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $630,838.
At Friday morning, Staar Surgical shares are up by 3.0%, trading at $22.51.
<h3>Get to Know Staar Surgical Better</h3>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Key Indicators: Staar Surgical's Financial Health</h3>
Revenue Growth: Staar Surgical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 10.31%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 77.31%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Staar Surgical exhibits below-average bottom-line performance with a current EPS of 0.2.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.09, Staar Surgical adopts a prudent financial strategy, indicating a balanced approach to debt management.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 49.67 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 3.17 is lower than the industry average, implying a discounted valuation for Staar Surgical's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 28.03 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000718937">Check Out The Full List Of Staar Surgical's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

BROADWOOD PARTNERS LP Takes a Bullish Stance: Acquires $630K In Staar Surgical Stock

It was revealed in a recent SEC filing that BROADWOOD PARTNERS LP, 10% Owner at Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) made a noteworthy insider purchase on December 19,.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000718937/000091957424007190//Archives/edgar/data/718937/000091957424007190/0000919574-24-007190-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, LP increased their investment in Staar Surgical by purchasing 80,200 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $1,947,539.
As of Thursday morning, Staar Surgical shares are up by 3.34%, currently priced at $25.07.
<h3>Discovering Staar Surgical: A Closer Look</h3>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Financial Insights: Staar Surgical</h3>
Positive Revenue Trend: Examining Staar Surgical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 77.31%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Staar Surgical exhibits below-average bottom-line performance with a current EPS of 0.2.
</li>
</ul>
Debt Management: Staar Surgical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 55.03 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.51 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 31.73 reflects market recognition of Staar Surgical's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000718937">Check Out The Full List Of Staar Surgical's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10% Owner Of Staar Surgical Purchased $1.95M In Stock

Press Releases

STAAR Surgical Experience Center Expands to Meet Growing Surgeon Demand

STAAR Surgical to Report Third Quarter Results on October 30, 2024

STAAR Surgical Reports Third Quarter 2024 Results

STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024)

STAAR Surgical to Participate in BTIG Ophthalmology Day

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results

Small Cap

STAA Investors Have Opportunity to Join STAAR Surgical Company Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA

Comments

Staar Surgical

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga